Compare NPKI & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NPKI | ORIC |
|---|---|---|
| Founded | 1932 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 973.9M |
| IPO Year | N/A | 2020 |
| Metric | NPKI | ORIC |
|---|---|---|
| Price | $12.59 | $9.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | $14.17 | ★ $19.50 |
| AVG Volume (30 Days) | 709.0K | ★ 1.3M |
| Earning Date | 10-30-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | ★ $259,372,000.00 | N/A |
| Revenue This Year | $26.96 | N/A |
| Revenue Next Year | $13.16 | N/A |
| P/E Ratio | $33.54 | ★ N/A |
| Revenue Growth | ★ 25.65 | N/A |
| 52 Week Low | $4.76 | $3.90 |
| 52 Week High | $14.00 | $14.93 |
| Indicator | NPKI | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 52.57 | 25.89 |
| Support Level | $12.84 | $10.45 |
| Resistance Level | $13.25 | $12.50 |
| Average True Range (ATR) | 0.37 | 0.69 |
| MACD | 0.02 | -0.19 |
| Stochastic Oscillator | 48.33 | 8.42 |
NPK International Inc is a temporary worksite access solutions company that manufactures, sells, and rents recyclable composite matting products, along with a full suite of services, including planning, logistics, and site restoration. The company generates majority of revenue from the rental of recyclable composite matting systems, along with related site construction and services to customers in various markets including power transmission, oil and natural gas exploration and production, pipeline, renewable energy, petrochemical, construction and other industries within the United States and United Kingdom.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.